Innovations and Challenges in Melanoma
First Cambridge Conference
July 2005
Innovations and challenges in melanoma: consensus statement from the first international conference
MB Atkins, DE Elder, R Essner, KT Flaherty, TF Gajewski, FG Haluska, P Hwu, U Keilholz, JM Kirkwood, JW Mier, MI Ross, CL Slingluff, VK Sondak, JA Sosman, MA Weinstock, and L King
Progress and prospects on melanoma: the way forward for early detection and reduced mortality
MA Weinstock
Genetic alterations in signaling pathways in melanoma
FG Haluska, H Tsao, H Wu, FS Haluska, A Lazar, and V Goel
Pathology of melanoma
DE Elder
Early stage melanoma: staging criteria and prognostic modeling
MI Ross
Sentinel lymph node biopsy and melanoma biology
R Essner
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment
TF Gajewski
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations
JM Kirkwood, S Moschos, and W Wang
Melanoma vaccines: where have we been and where are we going?
VK Sondak, MS Sabel, and JJ Mulé
Peptide and DC vaccines
CL Slingluff, Jr, VH Engelhard, and S Ferrone
Immune monitoring of T-cell responses in cancer vaccine development
U Keilholz and C Scheibenbogen
Cytokine-based and biochemotherapy for advanced melanoma
MB Atkins
Improving antitumor responses by circumventing immune regulatory mechanisms
G Lizée, LG Radvanyi, WW Overwijk, and P Hwu
Chemotherapy and targeted therapy combinations in advanced melanoma KT Flaherty
Targeting the MAP kinase pathway in the treatment of malignant melanoma
DJ Panka, MB Atkins, and JW Mier
Molecular targets in melanoma from angiogenesis to apoptosis
JA Sosman and I Puzanov
